Učitavanje...
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F(2α) receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrate...
Spremljeno u:
| Izdano u: | Clin Ophthalmol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5079698/ https://ncbi.nlm.nih.gov/pubmed/27799730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S103985 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|